Armida N. Sasunova

Armida N. Sasunova

Auto-generated profile, based on publicly available information

Armida N. Sasunova

Federal Research Centre of Nutrition, Biotechnology and Food Safety

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2021 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDI. I. Dedov
I. I. Dedov
MSMarina Shestakova
Marina Shestakova
GMG. A. Melnichenko
G. A. Melnichenko
NMN. V. Mazurina
N. V. Mazurina
EAE. N. Andreeva
E. N. Andreeva
МХМ. Б. Хамошина
М. Б. Хамошина
МЕЖДИСЦИПЛИНАРНЫЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ «ЛЕЧЕНИЕ ОЖИРЕНИЯ И КОМОРБИДНЫХ ЗАБОЛЕВАНИЙ»

1 January 2021 in Problems of Nutrition
Verified
Journal Article
Closed access
VVValentina Vorobyeva
Valentina Vorobyeva
IVIrina Vorobyeva
Irina Vorobyeva
SMSergey Morozov
Sergey Morozov
ASA.N. Sasunova
A.N. Sasunova
AKAlla Kochetkova
Alla Kochetkova
Vasily A. IsakovVasily A. Isakov
Vasily A. Isakov
Специализированные пищевые продукты для диетической коррекции рациона больных с неалкогольным стеатогепатитом

1 January 2022 in Problems of Nutrition
Verified
Journal Article
Closed access
ASA.N. Sasunova
A.N. Sasunova
SMSergey Morozov
Sergey Morozov
RSRoman Vladimirovich Sobolev
Roman Vladimirovich Sobolev
Vasily A. IsakovVasily A. Isakov
Vasily A. Isakov
AKAlla Kochetkova
Alla Kochetkova
IVIrina Vorobyeva
Irina Vorobyeva
Оценка эффективности использования специализированного пищевого продукта в составе диетотерапии пациентов с неалкогольным стеатогепатитом

12 October 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASArmida N. Sasunova
Armida N. Sasunova
AGAlexey Goncharov
Alexey Goncharov
SMSergey Morozov
Sergey Morozov
Vasily A. IsakovVasily A. Isakov
Vasily A. Isakov
Aim. To assess efficacy of dietary patterns modification with the use of specialized food in patients with non-alcoholic steatohepatitis (NASH). Materials and methods. We developed new specialized food (SPP2) based on literature data on the role of dietary patterns in pathogenesis of NASH. It contained -3 PUFAs, soluble dietary fiber, phospholipids, -lipoic acid, coenzyme Q10, L-carnitine, complex of vitamins. Patients with NASH (per EASL guidelines), were invited to participate in the study and were randomly assigned to receive either isocaloric diet (ICD) alone (based on the results of indirect calorimetry Cosmed, Italy) or isocaloric diet with specialized food (2 portions of SPP2 a day), for 14 days. Repeated examinations of body composition with phase angle analysis (InBody, Republic of Korea) and blood chemistry were performed at baseline (BL) and after 14 days (EOT). The patients were advised to follow usual physical activity during the study. Non-parametric statistics was used to compare BL and EOT characteristics in the groups. Results. The groups did not differ by age, proportion of females, and baseline characteristics of body composition. Adherence to the diet was 87.5% in the ICD group and 88.2% in the ICD+SPP group (p=0.65). Compliance with the use of SPP was 100%. In the ICD+SPP group significant reduction of body weight was achieved (117.530.1 kg initially, vs 114.928.8 kg at EOT; p=0.007), whereas in the ICD group it was not statistically significant (106.722.1 kg at BL vs 104.016.8 kg at EOT, respectively; p=0.07). In contrast to the ICD group, in those who received ICD+SPP significant decrease in cholesterol (5.31.3 mmol/L at BL vs 4.61.3 mmol/L at EOT; p=0.003), LDL (3.71.0 mmol/L vs 3.31.0 mmol/L, respectively; p=0.009), alkaline phosphatase (132.699.1 vs 112.087.0 U/L; p=0.04), GGT (54.533.2 vs 37.519.7 U/L; p=0.04), insulin resistance index (6.13.2 vs 3.21.5, respectively; p=0.04) was detected. Conclusion. Modification of dietary patterns with the use of a specialized food in combination with low-calorie diet allows achieving significant reduction of weight and improve lipid and carbohydrate metabolism, reduce severity of cholestasis in patients with NASH.

28 August 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASArmida N. Sasunova
Armida N. Sasunova
AGAlexey Goncharov
Alexey Goncharov
SMSergey Morozov
Sergey Morozov
VPVladimir Pilipenko
Vladimir Pilipenko
Vasily A. IsakovVasily A. Isakov
Vasily A. Isakov
Aim. The aim of this study was to identify the prevalence of steatosis degrees and stages of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) in connection with the presence of carbohydrate metabolism disorders, such as prediabetes and type 2 diabetes mellitus (DM). Materials and methods. Retrospective database search (4101 records) was performed. Vibration-controlled transient liver elastography with controlled attenuation parameter module was used for the assessment of liver steatosis and fibrosis. Based on the presence of carbohydrate metabolism disorders, subjects with MASLD were allocated to one of the following groups: MASLD without prediabetes or DM (group 1), MASLD with prediabetes (group 2) and MASLD with DM (group 3). Results. Proportion of patients with severe liver steatosis (S3) was lowest in the group 1 (61.9%), while no difference was found between groups 2 and 3 (74.3% vs 76.7%; p = 0.5). Moderate-to-severe liver fibrosis (stages F2–F4) was less widespread in the group 1 (24.1%); significant difference by this parameter was also revealed between groups 2 and 3 (34.0% vs 45.4%; p = 0.004). Proportion of patients with metabolic dysfunction-associated steatohepatitis was similar in groups 2 and 3 (33.9% vs 35.4%; p = 0.7), but was lower in the group 1 (26.7% vs 33.9% and 35.4%; p = 0.02 and p 0.001, respectively). Conclusion. Carbohydrate metabolism disorders are closely associated with progressive steatosis and liver fibrosis in patients with MASLD. No differences in the severity of liver steatosis was found between groups with prediabetes and T2DM, however, in T2DM, the prevalence of advanced/severe liver fibrosis was highest among all studied groups.

14 September 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASArmida N. Sasunova
Armida N. Sasunova
AGAlexey Goncharov
Alexey Goncharov
KGKamilat M. Gapparova
Kamilat M. Gapparova
Vasily A. IsakovVasily A. Isakov
Vasily A. Isakov
Aim. To study the impact of type 2 diabetes mellitus (DM2) on the severity of liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods. To conduct a paired case-control study 2989 patients were examined at the Federal Research Center of Nutrition, Biotechnology and Food Safety. Pairs were matched by gender and age and distributed into groups: NAFLD + DM2+ (n=313), NAFLD + DM2- (n=313) and a control group of patients without NAFLD and without DM2 (n=313). The severity of liver steatosis was determined by measuring the controlled attenuation parameter. The severity of liver fibrosis was determined by measuring the liver stiffness measurement. Body composition of the patients was determined using bioimpedance measurements. Indicators of lipid and carbohydrate metabolism, and the serum activity of liver enzymes was determined by standard biochemical methods. Results. In NAFLD + DM2+ group compared to NAFLD + DM2- group, and in NAFLDM + DM2-compared to the control group, weight, BMI, waist and hip circumference, waist-to-hip ratio were higher, while in all. In NAFLD + DM2+ and NAFLD + DM2- groups the volume of fat mass directly correlated with the level of blood triglycerides (r=0.21), HbA1с (r=0.32) and fasting blood glucose (r=0.35), and inversely correlated with high-density lipoproteins (r=-0.19). In NAFLD + DM2+ group versus NAFLD + DM2- group severe steatosis (S3, 78% versus 59.4%; p0.001) and severe fibrosis (F4, 8% vs 2.6%; p0.001) was more common; 70% of patients in the NAFLD + DM2- group had no liver fibrosis according to elastography (F0), while in the NAFLD + DM2+ group only 43.2% of patients had no liver fibrosis (p0.0001). Conclusion. When NAFLD is accompanied by DM2, there is an increase in total fat mass, the severity of steatosis and liver fibrosis, and an associated deterioration of lipid metabolism. More than half of these patients have various stages of liver fibrosis, which indicates the progressive nature of the disease.